SCHEDULE 13G/A: Janus Henderson Group Discloses 11.3% Stake in Vaxcyte, Inc.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a beneficial ownership of 11.3% in Vaxcyte, Inc.'s common stock as of April 30, 2025.

Summary

• Janus Henderson Group PLC reported beneficial ownership of 14,540,284 shares of Vaxcyte, Inc. common stock.
• This represents 11.3% of Vaxcyte, Inc.'s common stock.
• The filing is an Amendment No. 6 to a Schedule 13G.
• The date of the event requiring this filing was April 30, 2025.
• Janus Henderson Group PLC, through its indirect subsidiaries JHIUS, JHIUKL, and JHIAIFML, acts as registered investment advisers for Managed Portfolios.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a substantial and continued investment by Janus Henderson Group PLC in Vaxcyte, Inc., which can be interpreted as a positive signal of confidence from a major institutional investor.

Positives

• Janus Henderson Group PLC, a significant institutional investor, holds a substantial 11.3% stake in Vaxcyte, Inc., which can be interpreted as a signal of confidence in the company.
• The filing confirms that the shares are held in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.

Future Outlook

The document, a Schedule 13G filing, does not provide any forward-looking statements or guidance regarding Vaxcyte, Inc.'s future performance or strategic direction.

Management Comments

• The document does not contain direct quotes or paraphrased statements from Vaxcyte, Inc.'s management. It includes a certification from Janus Henderson Group PLC's Head of North America Compliance, Kristin Mariani, stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

This Schedule 13G filing primarily details an institutional investor's stake and does not provide specific insights into broader industry trends or Vaxcyte, Inc.'s competitive position within its sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake provides transparency regarding the ownership structure and may influence investor sentiment.

Key Dates

Keywords

Vaxcyte Inc., Janus Henderson Group PLC, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Adviser, Equity Stake